A phase II randomized double blind placebo-controlled parallel-group multicenter study of KRP-N118 in patients with Nocturia due to nocturnal polyuria
Latest Information Update: 18 Feb 2022
At a glance
- Drugs Lazuvapagon (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical; Sanwa Kagaku Kenkyusho
Most Recent Events
- 09 Nov 2018 Status changed from not yet recruiting to recruiting.
- 18 Sep 2018 New trial record